Advancing the Diagnosis of Sarcoidosis

Developing a blood-based diagnostic approach for sarcoidosis, founded on research conducted at a leading medical university.

Scroll to explore

Our Mission

A Rational Method for Diagnosing Sarcoidosis

Millions of people live with inflammatory diseases that are difficult to diagnose. At Anaxa, we are working to change that.

Watch Our Introduction

A brief video description of our mission and approach

The Challenge

A Disease That Remains Difficult to Diagnose

Sarcoidosis is a systemic inflammatory disease that can affect multiple organs, most commonly the lungs and lymph nodes. It is characterized by the formation of granulomas—organized clusters of immune cells—that may interfere with normal organ function.

Despite its impact, there is no single definitive test for sarcoidosis. Diagnosis typically relies on a combination of clinical assessment, imaging, laboratory tests, and invasive procedures such as biopsies.

Learn About Sarcoidosis

Multiple Organs Affected

Lungs, lymph nodes, heart, eyes, liver, skin

Complex Diagnosis

No single definitive test available

Invasive Procedures

Biopsies often required

Delayed Treatment

Late diagnosis impacts outcomes

Our Solution

A Blood-Based Diagnostic Approach

Through extensive analysis of patient samples at Karolinska Institutet, our research team identified a distinct immunological signal. Biomarker 143 was found to be significantly elevated in patients with sarcoidosis.

Based on this discovery, Anaxa is developing a non-invasive diagnostic blood test designed to support earlier and more reliable diagnosis.

1

Blood Sample Collection

Simple, non-invasive blood draw

2

Laboratory Analysis

Detection of Biomarker 143

3

Diagnostic Insight

Supporting clinical evaluation of suspected sarcoidosis

Scientific Foundation

Rooted in Academic Excellence

Anaxa is a spin-off from the Karolinska Institutet, one of the world's leading medical research institutions. Our work builds on cutting-edge research in translational immunology.

Academic Foundation

Our research originates from studies conducted at one of the world's leading medical universities, focusing on immune mechanisms and Biomarker 143 in sarcoidosis.

About Our Research

Validated Findings

Through analysis of extensive patient cohorts, Biomarker 143 was identified as being associated with sarcoidosis and confirmed using multiple analytical platforms.

Our Approach

Expert Leadership

Our team combines deep academic expertise in immunology with strategic business experience, bridging scientific discovery and diagnostic development.

Meet the Team

Let's Advance
Sarcoidosis Diagnosis
Together

For inquiries regarding Anaxa, partnership opportunities, or our research activities, we welcome you to get in touch. Whether you're a researcher, clinician, or potential partner, we'd love to hear from you.